49561-96-8

Usage

Uses

Used in Pharmaceutical Industry:
4-(Trifluoromethoxy)phenylacetonitrile is used as an intermediate in the synthesis of various pharmaceutical compounds for [application reason]. Its unique chemical structure allows for the development of new drugs with potential therapeutic benefits.
Used in Chemical Synthesis:
In the chemical industry, 4-(Trifluoromethoxy)phenylacetonitrile is used as a building block for the creation of more complex molecules with specific applications, such as agrochemicals, dyes, and other specialty chemicals.
Used in Research and Development:
4-(Trifluoromethoxy)phenylacetonitrile is also utilized in research and development for the exploration of new chemical reactions and the synthesis of novel compounds with potential applications in various fields.

InChI:InChI=1/C9H6F3NO/c10-9(11,12)14-8-3-1-7(2-4-8)5-6-13/h1-4H,5H2

Upstream product

• 50824-05-0 4-trifluoromethoxybenzyl bromide 
• 151-50-8 potassium cyanide 
• 773837-37-9 sodium cyanide 
• 587-18-8 4-trifluoromethoxy-benzoic acid ethyl ester 
• 1736-74-9 4-trifluoromethoxybenzyl alcohol 

Downstream Products

• 4315-07-5 4-(trifluoromethoxy)phenylacetic acid 
• 643013-21-2 4-[2-cyano-2-(4-trifluoromethoxyphenyl)vinyl]benzoic acid methyl ester 
• 170015-99-3 2-[4-(trifluoromethoxy)phenyl]ethylamine 
• 151157-62-9 1-(4-(trifluoromethoxy)phenyl)cyclobutane-1-carbonitrile 
• 173859-39-7 1-((4-trifluoromethoxy)phenyl)cyclopropanecarbonitrile 
• 1104643-47-1 tert-butyl cyano[4-(trifluoromethoxy)phenyl]acetate 
• 280110-83-0 C₉H₉F₃N₂O₂ 
• 1334718-88-5 5-(6-chloro-2-ethylimidazo[1,2-a]pyridin-3-yl)-3-(4-(trifluoromethoxy)benzyl)-1,2,4-oxadiazole 
• 1092532-45-0 1-cyano-1-(4-trifluoromethoxy-phenyl)cyclohexan-4-one 
• 1432048-71-9 3-hydroxy-1-[4-(trifluoromethoxy)phenyl]cyclobutanecarbonitrile 
• 1432048-77-5 3,3-dimethoxy-1-[4-(trifluoromethoxy)phenyl]cyclobutanecarboxamide 
• 1432097-55-6 cis-3-[(S)-hydroxy(pyridin-2-yl)methyl]-1-methyl-3-[4-(trifluoromethoxy)-phenyl]cyclobutanol 

Relevant academic research and scientific papers

17a-HYDROXYLASE/C17,20-LYASE INHIBITORS

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.

Anti-Inflammation Compounds

The present invention refers to: a compound having the general formula (I), wherein n is 0, 1, 2 or; m is 0, 1, 2 or 3; o is 0, 1, 2 or 3; W, X, Y and Z are independently selected from CH, N or N-oxide; A is NR4, C═O, C═S, OP(O)(O), P═O, CH2, or a heteroarly selected from the group consisting of (a), (b), (c), (d), (e), (f), (g); V is C═O, O, S, CH2, or NR5; as well as its use in treating inflammatory diseases such as asthma, COPD, inflammation post infection, arthritis, atherosclerosis, pain and dermatitis.

17α-HYDROXYLASE/C17,20-LYASE INHIBITORS

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.

ANTI-INFECTIVE COMPOUNDS

The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.

SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR

The present invention relates to compounds and methods useful as inhibitors of PPAR, particularly PPARδ, and for the treatment or prevention of PPAR-mediated diseases, including metabolic diseases.

PROCESS FOR PREPARING 2-(4-TRIFLUOROMETHOXYPHENYL)ETHYLAMINE AND 4-BROMOMETHYL-AND 4-CHLOROMETHYL-1-TRIFLUOROMETHOXYBENZENE

The invention relates to a process for preparing 2-(4-trifluoromethoxyphenyl)ethylamine in an advantageous manner by (a) converting trifluoromethoxybenzene by halomethylation into halogenomethyl-1-trifluoromethoxybenzene, (b) converting the halogenomethyl

Nitro-[2,1-b]imidazopyran compounds and antibacterial uses thereof

Methods, compounds and compositions are provided for inhibiting the growth of pathogenic microbes in vitro and of treatment of pathogenic bacterial infections, such as mycobacterial, Clostridium, Cryptosporidium and Helicobacter infections, in vivo using bicyclic nitroimidazole compounds of the formula (II): STR1 wherein R1 is hydrogen, halogen, loweralkyl, haloloweralkyl, cycloalkyl, heterocycle, substituted heterocycle and heterocyclicalkyl; X is oxygen, sulfur or NR2, where R2 is hydrogen, loweralkyl, aryl, cycloalkyl, heterocycle, substituted heterocycle, heterocyclicalkyl, COR3 or SO2 R4 CONR4 R5, where R3, R4 and R5 are independently selected from hydrogen, loweralkyl, aryl, alkylaryl, alkoxyalkyl, alkoxyaryl, alloxyalkoxyaryl, alkylheterocycle, and alkoxyheterocycle; n is 1, 2 or 3; Y and Z are independently selected from oxygen, CH2, CO, CR4 R5 or NR4, where R4 and R5 are as defined above; provided that when n is 2 or 3, the compounds of formula II can be additionally substituted as follows: STR2 wherein R6, R7, R8 and R9 are independently selected from hydrogen, loweralkyl, aryl, alkylaryl, alkoxyalkyl, alkoxyalkylaryl, alkoxyalkylheterocycle, alkylary2alkylaryl, alkylarylaryl, alkylcycloalkyl, alkoxyaryl, alkylheterocycle, and alkoxyheterocycle; and the pharmaceutically acceptable salts thereof.